Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma
Authors: Kamel Laribi, Alix Baugier de Materre, Yamina Touileb, Charles Boursot, Jeremy Sandrini, Doriane Cavalieri, Cédric Pastoret, Laurence de Leval, Olivier Tournilhac
Journal: HemaSphere (2022)

Angioimmunoblastic T-cell lymphoma (AITL) is a nodal T-cell lymphoma with a T-follicular helper (TFH) phenotype and aggressive clinical behavior. Molecular studies have shown recurrent mutations in TET2, DNMT3A, RHOA, and IDH1/2 in a significant proportion of cases.1,2 Treatment in the front-line setting is most frequently anthracycline-based regimen, which is associated with a high failure rate and frequent relapses. The prognosis for patients with relapsed/refractory (R/R) disease is poor with a median overall survival (OS) of 6 months.3 Hypomethylating agents (HMA) are the main treatment of high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in elderly patients, and the response rate to HMAs were correlated with TET2, IDH1/2, and DNMT3A mutations.4 Activity of HMAs against TFH-derived peripheral T-cell lymphoma (PTCL) was shown in previous case reports.5 The Lymphoma Study Association (LYSA) group reported a series of 12 patients with AITL treated with 5-azacytidine. Concomitant myeloid neoplasm (MDS/CMML) was present in 5 patients. The overall response (OR) and complete response (CR) rates were 75% and 50%, respectively. After a median follow-up of 27 months, the median progression-free survival (PFS) and OS were 15 months and 21 months, respectively.6 Overexpression of the antiapoptotic protein B-cell lymphoma 2(Bcl-2) was reported in AITL patients (43%–86%) and was strongly associated with advanced stage and higher international prognostic indices (IPI).7,8 Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, US-FDA approved alone or in combination in CLL and AML. Previous reports have shown that patient-derived cutaneous T-cell lymphoma (CTCL) cells exhibit a variable sensitivity to venetoclax correlated with baseline Bcl-2.9 King et al treated one R/R mycosis fungoides-CTCL patient with venetoclax monotherapy. The patient achieved PR. In vitro viability assays followed after 6 months of treatment showed no significant change in drug sensitivity, consistent with the absence of development of resistance to venetoclax.10 Here, we report the efficacy and safety of 5-azacytidine administered at 75 mg/m2 daily, subcutaneously, for 7 consecutive days, every 28 days, plus venetoclax administered at 400 mg daily, after dose escalation (100 mg at day 1, 200 mg at day 2, then 400 mg daily), until progression or unacceptable toxicity, in 5 patients with R/R AITL, enrolled in 2 centers in France, between April 2020 and February 2021. AITL diagnoses were all confirmed by 2 expert pathologists in the framework of the national program "Lymphopath," based on the criteria of the World Health Organization 2016 classification. By immunohistochemistry, the lymphoma cells had a CD10+PD1+ BCL6+ CXCL13± phenotype. Expression of BCL-2 was moderate in PD1– atypical cells in 3 cases and low in 2 cases compared with the level of expression of small reactive lymphoid cells (Figure 1).Figure 1.: FDG/PET imaging in patient 1. (A) FDG/PET imaging showing complete metabolic response after 3 cycles of AZA+VEN with disappearance of lymph nod and bone lesions. (B) FDG/PET imaging before AZA+VEN initiation showing cervical, axillary, mediastinal, mesenteric, retroperintoneal, and bone involvement. AZA+VEN = azacytidine and venetoclax; FDG/PET = fluorodeoxyglucose positron emission tomography.Molecular analysis was performed on lymph node biopsies collected at initial diagnosis. DNA was extracted from frozen or FFPE lymph node biopsies with a Maxwell Rapid Sample Concentrator (Promega, Madison, WI). We sequenced a panel of 16 genes dedicated to T-cell lymphomas (CARD11, CD28, DNMT3A, IDH1, IDH2, JAK3, KRAS, NRAS, PLCG1, RHOA, SETD2, STAT3, STAT5B, TET2, TNFAIP3, and TP53) from 100 ng of DNA. Libraries were generated in duplicate using an amplicon-based strategy with Advanta NGS Library Prep reagents on an Access ArrayTM 48.48 Integrated Fluidic Circuit (Fluidigm, San Francisco, CA) and sequenced on a NextSeq550 platform (Illumina, San Diego, CA) with a median coverage >1000×. Data were analyzed with a custom bioinformatic pipeline. Exonic nonsynonymous mutations with a variant allelic frequency >1% and at least 20 mutated reads were reported. Tumor responses included physical examination, chest and abdominal CT, and PET-CT and responses were assessed after 3 and 6 cycles of therapy by the attending physician following the 1999 Cheson criteria.11 The study was approved by a local ethics committee. Patient characteristics are summarized in Table 1. The median age was 71 years (range: 57–87), median IPI was 3 (range: 3–4), median previous lines of treatment was 2 (range: 1–6). No patient had associated myeloid neoplasm on initial staging of bone marrow biopsy and blood count. Table 1. - Clinical Characteristics and Patient Follow-up ID Age/Sex Phenotype (IHC) Mutations (VAF%) IPI at Diagnosis Number of Previous Therapy Previous Auto-HSCT 5-Azacytidine-Venotoclax (No. of Cycles) Best Response Allo-HSCT Relapse/Outcome Overall Survivala(months) AITL1 60/M CD10+PD1+ BCL6+CXCL13–BCL2±EBV– IDH2 p.Arg172Lys (5.8%)TET2 p.Tyr559Ter (26%) 3 6 1 6 CR Yes No/diedb 7.4 AITL2 71/M CD10+PD1+ BCL2+BCL6+ CXCL13+ EBV– IDH2 p.Arg172Lys (11.7%)RHOA p.Gly17Val (4.4%)TET2 p.Pro1131AsnfTer10 (19.1%) 4 1 0 10 CR No No/alive 9.2 AITL3 87/F CD10+PD1+ BCL6+CXCL13+ BCL2+ EBV+ DNMT3A p.Arg882Cys (33.3%)IDH2 p.Arg172Ser (15.6%)RHOA p.Gly17Val (5%)TET2 p.Arg1465Ter (21.2%)TET2 p.Leu1322Gln (11.5%) 4 2 0 12 CR No No/alive 11.5 AITL4 80/F CD10+PD1+ BCL6+ CXCL13–BCL2±EBV– IDH2 p.Arg172Lys (3.4%)RHOA p.Gly17Val (5.5%)TET2p.Glu1106ValfsTer23 (3.6%) 3 2 0 5 PD No Yes/died 5 AITL5 57/M CD10+PD1+ BCL6+CXCL13+ BCL2+EBV– DNMT3A p.Tyr735Thrfs44 (7%) 3 4 0 5 PRc No Yes/alive 8.5 aThe OS reported is from date of initiation of HMA + venetoclax.bThe patient died on the 34th day after transplantation secondary to veno-occlusive disease.cThe patient achieved partial response after 3 cycles of 5-Azacytidine+ venotoclax, however the treatment was stopped after cycle 5 because he developed pulmonary aspergillosis and he relapsed 1 month later.CR = complete response; IHC = immunohistochemistry; HSCT = hematopoietic stem cell transplantation; HMA = hypomethylating agent; IPI = international prognostic indices; OS = overall survival;PD = progression of disease; PR = partial response; VAF = variant allele frequency. All patients had received CHOP-like therapy and 1 patient had received previous autohematopoietic stem cell transplantation (HSCT). All received a median of 6 cycles (range 5–12 cycles) of 5-azacytidine plus venetoclax. One patient received additional rituximab because he had Epstein-Barr virus replication in the lymph node biopsy with 40% of EBER+ B cells. The OR and CR rates were 80% and 60%, respectively (Figure 1). One patient underwent allo-HSCT after achieving CR. He died on the 34th day after transplantation secondary to veno-occlusive disease. Two patients are still receiving treatment (Figure 2). Three out of 5 patients are alive. After a median follow-up of 8.5 months (range: 5–11), the median PFS is 7.54 months. The median OS is not reached. The OS at 1 year is 60%.Figure 2.: Swimming plots showing in months the course of treatment for each patient from the diagnosis. AZA + VEN = azacytidine and venetoclax.Most of the adverse events were hematological toxic effects. Neutropenia was reported in 5 patients including neutropenia grade 4 in 2 patients and febrile neutropenia in 1 patient. NGS analyses showed RHOA G17V mutations in 3 patients (60%). The epigenetic regulator TET2 was mutated in 4 patients (80%), and 1 out of 5 patients (20%) had 2 mutations. IDH2 mutations were detected in 4 patients (80%), while DNMT3A were detected in 3 (60%). Furthermore, the median variant allele frequency (VAF) of DNMT3A (20.1%) and TET2 mutations (20.1%) was higher than that of RHOA (5%) and IDH2 mutations (8.7%). These results are in direct lines with previous reports, suggesting that DNMT3A and TET2 mutations occur earlier and probably in precursor cells.1,2,12 The rationale for using epigenetic therapies in AITL is supported by several studies that have shown mutations in epigenetic genes. However, the mechanism of action of HMAs in AITL has not been clarified yet. It is hypothesized that HMA act on regulators of DNA methylation, supported by the overlap with the molecular signature of MDS. Nevertheless, previous studies reported a robust methylation immunophenotype profile in PTCL samples including AITL with the loss of 5-hydroxymethylcytosine in the absence of genetic alterations in the TET2, DNMT3A, and IDH2 epigenetic modifiers.13 This may explain the response to HMA irrespective of the mutational profile including TET2 mutational status in previous case reports,14 but it remains unanswered as to whether this may confer specific sensitivity to HMAs. Is there a direct effect on neoplastic T cells or other mechanisms? The BH3-mimetic, venetoclax is able to reinstate the apoptotic potential of tumor cells and therapy resistance induced by overexpression of Bcl-2 or loss of BH3-only protein function. However, durable response to venetoclax is attenuated by a variety of distinct resistance mechanisms including increased expression of antiapoptotic MCL-1 or BCL-XL leading to maintained cell survival and proliferation. Recent studies showed that the efficacy of venetoclax was improved when combined with agents down regulating MCL1 or BCL-XL such HMAs.15 These findings highlight the possible beneficial effects of a 5-azacytidine + venetoclax regimen with acceptable tolerance. However, a longer follow-up is needed. Further trials with ancillary molecular studies are required for a better understanding of this combination. ACKNOWLEDGMENTS The authors appreciate the contributions of the physicians and data manager who made this analysis possible, as well as the contributions made by the patients themselves. DISCLOSURES Outside this work, KL has received research grants from AbbVie, Novartis, Takeda, Roche, Amgen, and Sandoz as well as personal fees from AbbVie, Novartis, Sandoz, Celgene, Jansen, and Amgen. The other authors have no conflicts of interest to disclose.